The University of Puerto Rico Clinical Trials Unit (UPR-CTU) is a coalition/merge of the three previous independent Clinical Trials Sites associated to the AACTG, HVTN and PACTG Networks. The newly formed UPR-GTU will continue to have 3 Clinical Research Sites which will work with the Leadership Networks established to further advance the high priority areas related to: Vaccine Research and Development, Translational Research/Drug Development, Optimization of Clinical management, including Co-Morbidities and Prevention of Mother to Child Transmission of HIV. Letters confirming our affiliation to the following Networks are included in section h. (Consortium and Contractual Agreements): AIDS Clinical trials Group (ACTC5), International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) and the HIV Vaccine Trials Network (HVTN). The Goals of the UPR-CTU are to integrate three previously independent clinical research units into a single complex but operationally efficient Clinical Trials Unit. Improved efficiency and expansion of services will be the result of the integration/merge of specific units or functions within units. For example: a centralized pharmacy with better infrastructure will be able to provide quality services and expanded functions. Cost containment is expected since mayor infrastructure investments will be localized to a central site. Community interaction including community education and recruitment w II also be integrated or merged in order to maximize resources and outcomes. The UPR-CTU already has a centralized laboratory which has provided services and support to the three previously independent units. The scientific input and expertise of the Laboratory Director will be incorporated into the Executive Committee composed of the co-investigators. The UPR-CTU has the access and capacity to recruit the following populations: men and women living with HIV (mostly Hispanic minorities) either treatment naive or experienced, pregnant women living with HIV, infants born to women living with HIV, infants, children and adolescents exposed to HIV or infected with HIV, Low (behavioral) risk HIV negative volunteers (men and women), High risk heterosexual women (commercial sex workers, crack/drug users, sex partners of IDUs) and High risk MSM. Not only operational efficiency is expected but also, future research collaborations within networks will be simplified at the units. The expertise for vaccine trials, adolescent medicine, special populations, women (pregnant and non-pregnant) and minority issues just to mention a few, can be shared between the clinical research sites. ? ? ADMINISTRATIVE COMPONENT: ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01AI069415-01
Application #
7095444
Study Section
Special Emphasis Panel (ZAI1-AR-A (M1))
Program Officer
Power, Maureen E
Project Start
2007-02-01
Project End
2013-11-30
Budget Start
2007-02-01
Budget End
2007-11-30
Support Year
1
Fiscal Year
2007
Total Cost
$2,656,505
Indirect Cost
Name
University of Puerto Rico Med Sciences
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
948108063
City
San Juan
State
PR
Country
United States
Zip Code
00936
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Zorrilla, Carmen D; Mosquera, Ana MarĂ­a; Rabionet, Silvia et al. (2016) HIV and ZIKA in Pregnancy: Parallel Stories and New Challenges. Obstet Gynecol Int J 5:
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Riddler, Sharon A; Aga, Evgenia; Bosch, Ronald J et al. (2016) Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis 213:556-60

Showing the most recent 10 out of 67 publications